ROCKVILLE, M.D. and SUZHOU, China, Nov 6, 2022 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the results of a phase 3 clinical study (CREDIT-1) of tafolecimab (IBI306), a […]